If you purchased or provided reimbursement for generic metformin manufactured by certain defendants, you could be eligible for compensation from the settlement
NEW YORK — Scott+Scott, along with co-counsel, have obtained preliminary approval of a $5.5 million settlement against defendants Teva Pharmaceuticals USA, Inc., Granules Pharmaceuticals, Inc., and Heritage Pharmaceuticals, Inc in a long-running litigation pending in the United States District Court, District of New Jersey. The plaintiffs alleged that the defendants marketed and sold generic metformin that were contaminated with N-nitrosodimethylamine (“NDMA”), and that this metformin was not approved by the U.S. Food and Drug Administration and could not be sold to the public.
Consumers and third party payors who purchased or paid reimbursement for metformin manufactured by defendants may be eligible for compensation as part of this settlement.
Find out if your eligible by visiting this website: https://inremetforminsettlement.com/
The case is: In Re: Metformin Marketing and Sales Practices Litigation, No. 2:20-cv-2324-MCA-MAH
The Scott+Scott team of attorneys includes Partner Joseph P. Guglielmo, Senior Associate Michelle Conston, and Associate Andrew Stanko.